Contact this trialFirst, we need to learn more about you.
Anti-viral
Glecaprevir/Pibrentasvir (GLE/PIB) for Acute Hepatitis C
Recruiting2 awardsPhase 3
Baltimore, Maryland
This trial will help researchers understand if GLE/PIB is safe and effective for the treatment of acute HCV infection in adults and adolescents.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.